1620/Don

In re Patent Application of: Yongfeng Wang et al.

Application No.: 10/559,516

Filing Date: March 27, 2006

2-substituted phenyl-5, 7-dehydrocarbyl-3, 7-dihydropyrrolo [2, 3-d] pyrimidin-4-one

derivatives, the preparation and the

pharmaceutical use thereof

Group Art Unit: 1614

Examiner: Not Yet Assigned

Attorney Docket No.: 601/4

INFORMATION DISCLOSURE STATEMENT

Mail Stop: Amendment Commissioner of Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

For:

Applicant respectfully submits this Information Disclosure Statement, identification of the information, and copies thereof if required pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98 in order to comply with the duty of disclosure. The enclosed Form PTO SB/08A/B identifies the references of which Applicant is aware. The Examiner is respectfully requested to consider the information herein and make it of record in the subject application.

By checking this paragraph, this Information Disclosure Statement is being filed pursuant to 37 C.F.R. § 1.97(b) within three months of the filing date of the application or before the application has received a substantive Office Action. Accordingly, no fee is necessary; however, should the Patent Office determine that a fee is due, the Commissioner is authorized to charge any such fee to Deposit Account No. 11-0223.

By checking this paragraph, this Information Disclosure Statement is being filed pursuant to 37 C.F.R. § 1.97(c) before the mailing date of a Final Action, a Notice of Allowance, or close of prosecution. Accordingly included herewith is:

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS: Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: June 19, 2006 Signature: Uta h. Word Krala Print Name: Ute H. Woitkowsh



Application No.: 10/559,516 Attorney Docket No.: 601/4 a completed Credit Card form to cover the fee under 37 C.F.R. § 1.17(p), the Commissioner is authorized to charge any further fee to Deposit Account No. 11-0223; or a statement below under 37 C.F.R. § 1.97(e). By checking this paragraph, this Information Disclosure Statement is being filed pursuant to 37 C.F.R. § 1.97(d) after the mailing date of a Final Action, a Notice of Allowance, or close of prosecution, but before payment of the issue fee. Accordingly included herewith are: a check to cover the fee under 37 C.F.R. § 1.17(p), the Commissioner is authorized to charge any further fee to Deposit Account No. 11-0223; and a statement below under 37 C.F.R. § 1.97(e). Statement Pursuant to 37 C.F.R. § 1.97(e): By checking this paragraph, the undersigned states that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior the filing of this Information Disclosure Statement; or By checking this paragraph, the undersigned states that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent in a counterpart foreign application, and, the undersigned, after making reasonable inquiry, believes that no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. Respectfully submitted Dated: June 19, 2006 Bv:

> Timothy X. Gibson Registration No. 40,618

KAPLAN GILMAN GIBSON & DERNIER LLP

900 Route 9 North

Woodbridge, New Jersey 07095

Telephone (732) 634-7634 Attorneys for Applicant

FACtions/Beijing Sunhope -601/601-4/601-4 - Information Disclosure Statement.doc

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 12950 required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DESCI STATEMENT BY

Complete if Known			
Application Number	10/559,516		
Filing Date	December 6, 2005		
First Named Inventor	Yongfeng Wang		
Art Unit	1614		
Examiner Name	Not Yet Assigned		
Attorney Docket Number	601/4		

Sheet 1 of

			U. S. PATENT D	OCUMENTS	
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	Number-Kind Code ^{2 (# known}	Number-Kind Code ² (* **********************************			1 iguico / ippou
		US-			
1-1		US-	 		
	1	US-			
		US-			
	 	US-			
v		US-			
		US-			
	 	US-			
-		US-			
	 	US-			
	 	US-			,
	1	US-			
	<u> </u>	US-			

	-	FORE	IGN PATENT DOCL	JMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ "Number ⁴ "Kind Code ⁵ (<i>if known</i>)	MM-DD-YYYY		Or Relevant Figures Appear	Τ°
	BA	EP 0 812 845 A1	12-17-1997	Pfizer Limtied		
						L
						_
						<u>L</u>

Examiner	·-	•	Date	
Signature			Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.